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ABSTRACT: 43 
 44 
New multicomponent solid forms of sildenafil have been discovered 45 
by means of a combined virtual/experimental cocrystal screening. Coformer 46 
selection of candidates was conducted based on an in silico screening method from 47 
a database of more than 2000 organic compounds, and the intensive experimental 48 
screen produced 23 new solid forms. Since the 12 coformers chosen have a 49 
combination of phenol and carboxylic acid groups, a variety of cocrystals, salts, and 50 
hybrid salt-cocrystals were discovered and characterized. 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
59 
1. INTRODUCTION 60 
 61 
Cocrystals of active pharmaceutical ingredients (APIs) have received massive attention over the past 62 
decade because they offer many opportunities to improve physicochemical properties of drugs.1,2 63 
Indeed, solubility is one of the most important properties for a drug compound since it has a direct 64 
impact on bioavailability, and the cocrystal approach is a versatile toolbox to tune this and another 65 
important property3,4 such as stability5 because of the high number of available potential coformers. 66 
On February 2018, the Food and Drug Administration (FDA) released a final guidance titled 67 
“Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry”,6 providing applicants 68 
planning to submit new drug applications with information on the regulatory classification of 69 
pharmaceutical cocrystals, classifying them as a new form of the API, comparable in that respect to 70 
polymorphs, hydrates, salts, etc. The FDA asks the applicants to provide evidence to demonstrate that 71 
“both the API and coformers are present in the unit cell” and “the component API and coformer co-exist 72 
in the cocrystal which interact nonionically”. The FDA guidance suggests that the applicant consider the 73 
difference of ΔpKa between the API and the coformer or to provide evidence that proton transfer has not 74 
occurred in the lattice by means of spectroscopic tools or other orthogonal approaches. Thus, from a 75 
regulatory point of view, it is very important to assess the proton transfer in a multicomponent 76 
Sildenafil, the active principle of Viagra, is the first oral drug used for the medical treatment of erectile 77 
dysfunction in elderly patients, and it was initially used as an antihypertensive drug8,9 but due to its 78 
poor aqueous solubility and low bioavailability it is generally formulated as sildenafil citrate.10 This 79 
solid form still exhibits moderate bioavailability, and this is the reason why some efforts have been 80 
conducted to discover new salts and cocrystals with enhanced physicochemical properties. In this sense, 81 
a sildenafil/acetylsalicylic cocrystal exhibiting enhanced intrinsic dissolution rate compared to sildenafil 82 
citrate has been reported.11 Moreover, pharmacokinetics of salts and cocrystals of sildenafil with 83 
dicarboxylic acids has been studied, and the glutarate salt was revealed to be a good candidate for 84 
alternative formulation of the citrate salt.12 The crystal structures of sildenafil base, sildenafil citrate 85 
monohydrate, sildenafil saccharinate, and sildenafil acesulfamate have been published in the 86 
literature,13,14 and some of us have described a polymorph of sildenafil free base and new 87 
solvates.15,16 With the aim to discover new multicomponent forms and extend the solid state 88 
knowledge of this important API, we have conducted a combined virtual/experimental salt/cocrystal 89 
screening by using a broad set of thermodynamic and kinetic experimental conditions. Twenty-three 90 
new solid forms of sildenafil, including salts, cocrystals, and hybrid salt−cocrystals, have been  91 
discovered and some of their crystal structures solved.  92 
 93 
 94 
 95 
 96 
  97 
2. MATERIALS AND METHODS 98 
 99 
2.1. Materials. Sildenafil (SIL) used in this study was of reagent grade and used as received from 100 
Polpharma (form I). The coformers quercetin (QUE), methyl gallate (MEG), tartaric acid (TAR), 3-101 
hydroxybenzoic acid (3-HBA), 4-hydroxybenzoic acid (4-HBA), resorcinol (RES), 3,4-102 
dihydroxybenzoic acid (3,4-DHBA), and caffeic acid (CAF) were purchased from Sigma-Aldrich. 103 
 104 
2.2. Methods. 2.2.1. Virtual Cocrystal Screening. For each compound, the molecule was drawn in an 105 
extended conformation and energy minimized using the molecular mechanics methods implemented in 106 
TorchLite.17 Gaussian 09 was used to optimize the geometry and calculate the MEPS on the 0.002 Bohr 107 
Å−3 electron density isosurface using density functional theory (DFT) and a B3LYP/6-31G* basis 108 
set.18 The MEPS was converted into SSIPs using in-house software.19 109 
2.2.2. Cocrystal Screening. Screening through liquid assisted grinding experiments (LAG) was 110 
conducted by grinding 20−35 mg of a 1:1 mixture of SIL and each coformer together with one drop of 111 
different solvents using a Retsch MM 2000 grinding mill. The samples were placed in 2 mL volume 112 
stainless steel jars, along with two stainless tungsten grinding balls of 3 mm diameter. Grinding was 113 
performed for 15−30 min, with a frequency of the mill of 30 Hz. Finally, the samples were collected 114 
immediately without prior drying for powder X-ray diffraction (PXRD) analysis. The formation of a 115 
new solid form was determined by comparing PXRD patterns of starting materials and products from 116 
cocrystal screening LAG experiments. Screening through reaction crystallization (RC) was conducted 117 
by preparing a saturated solution of the most soluble component (SIL or coformer) in different solvents 118 
in a sealed vial under stirring. A small quantity of the less soluble component was added until it did not 119 
dissolve anymore. The suspension was stirred at different times, and the resulting solids were filtered 120 
and analyzed by PXRD. Screening through solvent mediated transformations (SMT) were conducted by 121 
preparing suspensions of SIL and coformer in different molar ratios (40−1200mg of the final mixture) in 122 
selected solvents. The sealed vials were stirred for different times, and the resulting solids were filtered 123 
and analyzed by PXRD. 124 
2.2.3. Solution Crystallization. Solutions of SIL/coformer in a 1:1 molar ratio (10−20 mg of the final 125 
mixture) were prepared in different solvents and heated in a heating stainless steel block. The heater was 126 
switched off, and the solutions were allowed to slowly cool down to 25°C inside the heating block. The 127 
samples which did not crystallize were tightly sealed and kept at 25 °C until precipitation was observed. 128 
2.2.4. Synthesis of the Different Crystal Forms of Sildenafil. Details of synthesis and characterization of 129 
each form can be found in Supporting Information (see section 1 and Table S1). Stoichiometry has been 130 
assessed based on NMR and thermogravimetric analysis (TGA) measurements when the crystal 131 
structure is not available. In those cases where the crystal structure has not been solved, the definition of 132 
the form as a salt or a cocrystal has been done based on the probability of proton transfer determined 133 
with eq 3. 134 
Twenty-three multicomponent forms of SIL (cocrystals, salts, and hybrid salt−cocrystal) have been 135 
obtained through a cocrystal screening with 8 out of the 12 coformers used. Five cocrystal forms of SIL 136 
have been obtained with three coformers: two forms with quercetin in a 1:1 stoichiometry (one as an 137 
isopronanol solvate, SILQUE I, and one as a tetrahydrofuran solvate, SIL-QUE II); two with resorcinol 138 
in two different stoichiometries (one in a 1:1 molar ratio, SIL-RES I, and one in a 1:2 molar ratio, SIL-139 
RES II); one form with methyl gallate in a 1:1 stoichiometry, SIL-MEG. Fourteen salts of SIL have been 140 
obtained with five coformers: one form with 3,4-dihydroxybenzoic acid in a 1:1 stoichiometry as an 141 
isopropanol solvate, SIL-3,4-DHBA I; four forms with tartaric acid in two different stoichiometries: two 142 
in a 1:1 molar ratio (an anhydrous form, SIL-TAR I, and an isopropanol solvate, SIL-TAR III); two in a 143 
2:1 molar ratio (an anhydrous form, SIL-TAR II, and an isopropanol solvate, SIL-TAR IV); two forms 144 
with caffeic acid in a 2:3 stoichiometry (one as an anhydrous form, SIL-CAF I, and one as a 145 
monohydrate, SIL-CAF II); three forms with 3-hydroxybenzoic acid in a 1:1 stoichiometry (one as an 146 
acetonitrile solvate, SIL-3-HBA I, one as a tetrahydrofuran solvate sesquihydrate, SIL-3-HBA II, and 147 
one as an anhydrous form, SIL-3-HBA III); four forms with 4-hydroxybenzoic acid in a 1:1 148 
stoichiometry (two as anhydrous forms, SIL-4-HBA I and SIL-4-HBA III, one as a hemiisopropanol 149 
solvate, SIL-4-HBA II, and one as a tetrahydrofuran solvate, SIL-4-HBA IV). Four hybrid salt-cocrystal 150 
forms of SIL have been obtained with two coformers: three forms with 3,4-dihydroxybenzoic acid in 151 
two different stoichiometries (two of them in a 1:2 molar ratio as acetonitrile solvates, SIL-3,4-DHBA II 152 
and SIL-3,4-DHBA III, and one in a 2:3 molar ratio as a dehydrate, SIL-3,4-DHBA IV) and finally one 153 
form with 3-hydroxybenzoic acid in a 2:3 stoichiometry as a dehydrate, SIL-3-HBA IV. 154 
2.2.5. X-ray Crystallographic Analysis. Single crystal X-ray diffraction intensity data of the different 155 
crystal forms of sildenafil were collected using a D8 Venture system equipped with a multilayer 156 
monochromator and a Mo microfocus (λ = 0.71073 Å). Frames were integrated with the Bruker SAINT 157 
software package using a SAINT algorithm. Data were corrected for absorption effects using the 158 
multiscan method (SADABS).20 The structures were solved and refined using the Bruker SHELXTL 159 
Software Package, a computer program for automatic solution of crystal structures and refined by 160 
fullmatrix least-squares method with ShelXle Version 4.8.0, a Qt graphical user interface for SHELXL 161 
computer program.21 162 
Powder X-ray diffraction patterns were obtained on a PANalytical X’Pert PRO MPD diffractometer in 163 
transmission configuration using Cu Kα1 + 2 radiation (λ = 1.5406 Å) with a focusing elliptic mirror 164 
and a PIXcel detector working at a maximum detector’s active length of 3.347°. Configuration of 165 
convergent beam with a focalizing mirror and a transmission geometry with flat sample sandwiched 166 
between low absorbing films measuring from 2 to 40° in 2θ, with a step size of 0.026° or from 2 to 70° 167 
in 2θ, with a step size of 0.013° with measuring times of 30 min to 4 h. The powder diffractograms were 168 
indexed, and the lattice parameters were refined by means of LeBail fits by means of Dicvol04,22 and 169 
the space groups were determined from the systematic absences. A summary of crystal data and relevant 170 
refinement parameters are given in Tables 1 and 2. 171 
2.2.6. Differential Scanning Calorimetry (DSC). Differential scanning calorimetry analysis were carried 172 
out by means of a Mettler-Toledo DSC-822e calorimeter. Experimental conditions: aluminium crucibles 173 
of 40 μL volume, atmosphere of dry nitrogen with a 50 mL/min flow rate, and heating rate of 10 °C/min. 174 
The calorimeter was calibrated with indium of 99.99% purity (m.p.: 156.4 °C, ΔH: 28.55 J/g). 175 
2.2.7. Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed on a Mettler-176 
Toledo TGA-851e thermobalance. Experimental conditions: alumina crucibles of 70 μL volume, 177 
atmosphere of dry nitrogen with 50 mL/min flow rate, and a heating rate of 10 °C/min. 178 
2.2.8. Nuclear Magnetic Resonance (NMR). Proton nuclear magnetic resonance (1H NMR) spectra was 179 
recorded on a Varian Mercury 400 (400 MHz). Chemical shifts for proton are reported in parts per 180 
million (ppm) downfield from tetramethylsilane and are referenced to residual proton in the NMR 181 
solvent (DMSO-d6: δ 2.50). Experimental conditions: delay: 1; pulse: 45°; scans: 32 or 64. 182 
2.2.9. Dissolution Study. The dissolution measurements were carried out only with the solid forms that 183 
could be obtained pure in amounts sufficient to perform a dissolution study: pure sildenafil, salts of 184 
sildenafil with citric acid, tartaric acid, 3-HBA and 3,4-DHBA, a cocrystals with RES, QUE, and two 185 
hybrid salt-cocrystals of sildenafil with 3,4-DHBA. The dissolution was determined in 0.1 N HCl (pH 186 
1.2), phosphate buffer pH 6.5, and a biorelevant dissolution medium fasted state simulated intestinal 187 
fluid (FaSSIF) at 25 °C. For dissolution studies 40 mg of crystalline compounds were added to the 188 
dissolution medium stirred at 100 rpm over 24 h, and samples were withdrawn at 1 and 24 h. The 189 
amount of SIL dissolved in 1 h (D1h) and 24 h (D24h) was determined using the HPLC technique. The 190 
details about dissolution medium and HPLC method are provided in Supporting Informatiom. 191 
 192 
 193 
  194 
3. RESULTS AND DISCUSSION 195 
 196 
3.1. Virtual Cocrystal Screen. We selected the coformers for experimental screening based on the 197 
virtual cocrystal screening methodology developed by some of us to predict the probability of cocrystal 198 
formation.23 This computational tool has been validated using experimental data extracted from the 199 
literature. 200 
The difference between the calculated energy of the cocrystal and the pure components was used to rank 201 
potential cofomers.24 This approach uses surface site interaction points (SSIPs) calculated from the ab 202 
initio molecular electrostatic potential surface (MEPS) of the isolated molecule in the gas phase.19,25 203 
The interaction of a molecule with its environment is described by a discrete set of SSIPs, each 204 
represented by an interaction parameter, εi, which is positive for a H-bond donor site (or positive region 205 
on the MEPS) and negative for a H-bond acceptor site (or negative region on the MEPS). The energy of 206 
interaction between two SSIPs, i and j, is given by the product εiεj. We assume that pairwise interactions 207 
between SSIPs are optimized in a solid, and this provides a method for evaluating the interaction site 208 
pairing energy of a solid without knowledge of the crystal structure.26 The most positive SSIP is paired 209 
with the most negative SSIP, the next most positive SSIP with the next most negative, and so on, giving 210 
a hierarchical list of interactions.27,28 This interaction site pairing strategy provides a straightforward 211 
method for estimating the energy of a solid, E (eq 1). The same approach can be used to estimate the 212 
energy of a cocrystal, and the difference between the interaction site pairing energies of the cocrystal 213 
and the pure components, ΔE, can be used to estimate the probability of cocrystal formation (eq 2). 214 
 215 
E = Σεiεj  (1) 216 
 217 
 (2) 218 
 219 
where E1, E2, and Ecc are the interaction site pairing energies of the pure solids, 1 and 2, and a 1:1 220 
cocrystal respectively. Note that this definition means that ΔE is always positive, and a large value 221 
indicates a high probability of cocrystal formation.  222 
Some of us have previously applied the method to successfully predict the formation of new 223 
cocrystals,29,30 and in this work we have followed this theoretical approach to guide the selection of a 224 
limited number of coformers to test experimentally. Thus, the difference between the interaction site 225 
pairing energies of the 1:1 cocrystal and the pure components was calculated for each 226 
sildenafil/coformer combination using a coformer database which contains more than 2000 organic 227 
compounds (including 860 products from the GRAS list). The coformers were ranked in order of 228 
decreasing ΔE, and only 12 coformers were chosen from the top 100 compounds according to toxicity 229 
criteria and probability of success in a cocrystallization experiment (Table 3). This theoretical approach 230 
defines an energy threshold of 11kJ/mol where the probability of cocrystal formation is higher than 231 
50%. Thus, only coformers with ΔE > 11 kJ/mol were chosen for experimental screening 232 
Since sildenafil has a strong basic group, the formation of salts with strong carboxylic acids is expected. 233 
In fact, the formation of a salt or a cocrystal can be assessed based on the “rule of thumb”31 which 234 
states that salts are formed when ΔpKa [pKa(base) − pKa(acid)] ≥ 3, and a cocrystal is expected when 235 
this value is ≤0, the combinations with a value 0 ≤ [pKa(base) − pKa(acid)] ≤ 3 being much less reliable 236 
and falling around a “salt-cocrystal continuum” region.32 This uncertainty motivated the analysis and 237 
correlation by Cruz-Cabeza33 of a big set of experimental cocrystal/salt data in order to develop a more 238 
reliable equation to predict the salt/cocrystal outcome. According to this statistical analysis, eq 3 allows 239 
prediction of the probability of proton transfer around the region of ΔpKa values between −1 and 4. 240 
 241 
P(%) = 17ΔpKa + 28  (3) 242 
 243 
Sildenafil has a basic functional group (piperazine) with a pKa value of 6.78,34 and we have applied this 244 
statistical approach to the coformers with acidic groups selected from the virtual cocrystal screening to 245 
assess the probability of salt formation (Table 4). Coformers with acidic groups such as 246 
(3hydroxybenzoic acid, 4-hydroxybenzoic acid, caffeic acid, 3,4-dihydroxybenzoic acid, and tartaric 247 
acid) were expected to form salts. However, salt stoichiometry is an important outcome not always easy 248 
to predict because hybrid salt−cocrystal forms are also possible. In this sense, there are interesting 249 
examples in the literature with unexpected stoichiometries due to the presence of nonionized molecules 250 
in the crystal structure such as the p-coumaric acid/quinine39 or the trans-N,N′-251 
dibenzyldiaminocyclohexane/2,3-dichlorophenylacetic acid40 hybrid salt−cocrystals. Moreover, 252 
Aakeröy et al.41 suggested in a structural analysis of more than 80 cocrystals and salts formed between 253 
carboxylic acids and Nheterocycles that the formation of unexpected hybrid salt−cocrystals could be 254 
because carboxylate moieties are not readily satisfied by a single hydrogen-bond donor making 255 
necessary the presence of neutral carboxylic acids in the crystal structure. We have examined the 256 
Cambridge Structural Database (version 5.39, 2018) in order to assess the formation of hybrid 257 
salt−cocrystal forms in multicomponent crystals containing a piperazine ring (the basic group of 258 
sildenafil) and a carboxylic acid (Figure 3). 259 
A total of 247 crystal structures containing atomic coordinates were found and classified as salt, 260 
cocrystal, or hybrid salt−cocrystal according to the C−O bond lengths of the carboxylate moiety. 261 
Although 184 structures showed total proton transfer between donor and acceptor, 63 of them revealed 262 
that cocrystals or mixed salt-cocrystals were formed. This encouraged us to test the carboxylic acids 263 
previously chosen in the virtual cocrystal prediction. Table 5 summarizes the results of this structural 264 
analysis. 265 
3.2. Salt/Cocrystal Screening. With the aim to discover new salts or cocrystals of sildenafil ,an 266 
extensive multicomponent solid forms screening was conducted by using a broad set of thermodynamic 267 
and kinetic experimental conditions from a variety of 54 solvents,42 which produced 194 individual 268 
crystalline solids (see Supporting Information for experimental and characterization details). 269 
3.3. Crystal Structures Analysis. The crystal structures of 5 out of the new 23 forms of sildenafil have 270 
been solved by single crystal X-ray diffraction, and the following analysis shows that in all cases salts or 271 
hybrid salt-cocrystals have been formed with tartaric acid, 3-hydroxybenzoic acid, and 3,4-272 
dihydroxibenzoic acid. 273 
3.3.1. Tartaric Acid Salt Isopropanol Hemisolvate (SIL-TAR IV). Tartaric acid salt isopropanol 274 
hemisolvate crystallizes with one molecule of sildenafil cation, half molecule of tartrate dianion, and 275 
half disordered molecule of isopropanol in the asymmetric unit. Transfer of both protons of tartaric acid 276 
has been deduced since tartrate C−O distances are 1.183(9) and 1.232(8) Å. The dianion, which shows 277 
disorder between two conformations (in a 1:1 ratio), is encapsulated between two molecules of sildenafil 278 
establishing strong charge-assisted hydrogen bonds. Sildenafil/tartrate cages are packed with a 279 
combination of electrostatic interactions between sulphonamide moieties in a self-association fashion 280 
and weak hydrogen bonds between N-methylpyrazole rings (Figures 4 and 5). Molecular cavities are 281 
present and occupied by disordered molecules of isopropanol. 282 
3.3.2. Hybrid 3-Hydroxybenzoic Acid Salt−Cocrystal Monohydrate (SIL-3-HBA IV). The hybrid 283 
salt−cocrystal formed by 3-hydroxybenzoic acid and sildenafil crystallizes with one molecule of 284 
sildenafil cation, one molecule of the carboxylate, half molecule of the carboxylic acid, and one 285 
molecule of water in the asymmetric unit. Chains of selfassembled sildenafil cations are formed through 286 
strong hydrogen bonds between the piperazinium ring and the carbonylic oxygen. As expected, strong 287 
charge-assisted hydrogen bonds are formed between the carboxylate anion and the piperazinium cation, 288 
but one molecule of the nonionized carboxylic acid interacts with the carboxylate anion via the phenol 289 
and carboxylic hydrogen in an alternate manner (Figure 9). Weak antiparallel dipole−dipole interactions 290 
between stacked pyrimidinone rings are established conferring extra stabilization to the crystal (Figure 291 
8). 292 
In addition, one molecule of water is also present acting as a bridge between carboxylates (Figure 6). 293 
Nonionized 3-hydroxybenzoic acid molecules are located in channels establishing strong hydrogen 294 
bonds with other 3-hydroxybenzoate molecules (Figure 7). 295 
3.3.3. 3-Hydroxybenzoic Acid Salt THF Hemisolvate Sesquihydrate (SIL-3-HBA II). The salt formed 296 
by 3-hydroxybenzoic acid and sildenafil crystallizes with one molecule of sildenafil cation, one 297 
molecule of the carboxylate, half disordered molecule of THF, and 1.5 molecules of water in the 298 
asymmetric unit. In spite of the different degree of proton transfer, this solid form is isostructural to the 299 
hybrid 3-hydroxybenzoic acid saltcocrystal, and the same interactions between sildenafil and 3-300 
hydroxybenzoate molecules are established. Moreover, identical channels are formed but filled by 301 
disordered tetrahydrofuran and water molecules instead of molecules of 3-hydroxybenzoic acid. Only 302 
small differences between both structures are present like, for instance, centroid−centroid distances 303 
measured betwee pyrimidinone rings and torsion angles of propyl groups (Figure 8). 304 
3.3.4. Hybrid 3,4-Dihydroxybenzoic Acid Salt−Cocrystal Monohydrate (SIL-3,4-DHBA IV). The 305 
hybrid salt-cocrystal formed by 3,4-dihydroxybenzoic acid and sildenafil crystallizes with one molecule 306 
of sildenafil cations, one molecule of the carboxylate, half molecule of the carboxylic acid, and one 307 
molecule of water in the asymmetric unit. This solid form is isostructural to the hybrid 3-308 
hydroxybenzoic acid salt−cocrystal. The presence of an extra phenol group in the 3,4-dihydroxybenzoic 309 
acid only reinforces the same packing without disrupting any of the main observed interactions in the 310 
hybrid 3-hydroxybenzoic acid salt−cocrystal. Figure 9 shows chains of carboxylate molecules linked by 311 
water molecules in both structures. 312 
3.3.5. Hybrid 3,4-Dihydroxybenzoic Acid Salt−Cocrystal Acetonitrile Disolvate (SIL-3,4-DHBA II). 313 
The hybrid 3,4-dihydroxybenzoic acid salt−cocrystal acetonitrile disolvate crystallizes with one 314 
molecule of the sildenafil cation, one molecule of the carboxylate, one molecule of the carboxylic acid, 315 
and two molecules of acetonitrile in the asymmetric unit. In a similar way that the tartaric acid salt, 316 
instead of catemeric chains of sildenafil cations, self-assembled dimers are formed through charge-317 
assisted hydrogen bonds (Figure 10). 318 
However, the antiparallel dipole−dipole interactions between stacked pyrimidinone rings are not 319 
observed in this form. This is the only structure of this family of hybrid salts−cocrystals where water is 320 
not present, and this produces a different architecture of the coformer self-assembling, which consists of 321 
layers of alternate carboxylic/carboxylate interactions (Figure 11). 322 
3.4. Dissolution Study. The dissolution studies were carried out at pH 1.2, pH 6.5, and FaSSIF (pH 323 
6.5), which represent the average pH values of the fast state stomach and intestine, respectively. SIL has 324 
pH dependent solubility which decreases with an increase in pH. One of the major challenges in the 325 
dissolution study of multicomponent entities is continuous change in the solution composition due to 326 
precipitation of either of the component over the dissolution testing period. The solubility data generated 327 
may be erroneous due to limitations of the analytical method; for example, estimations carried out by 328 
UV spectrophotometry are subject to the overlap in the absorption spectra of the two components. We 329 
have used the HPLC method to quantify the amount of SIL dissolved; hence we see some difference in 330 
reported dissolutions compared to the previous SIL salt dissolution data reported.43 Figures 12, 13, and 331 
14 (and Figures S75−S77 of the Supporting Information) show the dissolution data. 332 
At pH 1.2 the amount dissolved from SIL salts was significantly higher than the cocrystals and the 333 
hybrid salt−cocrystal forms. The hybrid salt−cocrystals showed poor dissolution performance compared 334 
to cocrystals. The D1h and D24h values for SIL-TAR I were higher than for SIL-CIT, a commercially 335 
used salt of SIL. At pH 1.2 in the salt category SILTAR > SIL-3-HBA I > SIL-CIT > SIL-3,4-DHBA I. 336 
On the other hand D1h for SIL-RES II > SIL-QUE I and SIL-QUE II. As expected, the amount 337 
dissolved at pH 6.5 was at least 10 times lower than the amount dissolved at pH 1.2. But in both 338 
conditions, the amount of SIL dissolved was significantly higher for salts than for cocrystals and hybrid 339 
salt−cocrystals. Most of the cocrystals and hybrid salt−cocrystals did not provide any release of SIL at 340 
pH 6.5 or even in FaSSIF, which contains an additive like lecithin included in the dissolution media. 341 
Thus, although an exhaustive solubility study of the new forms was not the main objective of this 342 
research, our data suggest that SILTAR could be a potential alternative (in terms of bioavailability) to 343 
the commercial citrate salt of sildenafil. 344 
 345 
 346 
 347 
 348 
349 
4. CONCLUSION 350 
 351 
In summary, we have revisited the multicomponent solid form landscape of sildenafil by conducting a 352 
combined virtual and experimental screening. Twenty-three new solid forms have been discovered and 353 
characterized, and dissolution data have been measured for some of the solid forms suggesting the new 354 
tartrate salt as a potential alternative to the marketed citrate salt. The analysis of the five crystal 355 
structures solved by SXRD showed a variety of salts and hybrid salt−cocrystals with different hydrogen 356 
bond architectures and presence of solvent channels. This study extends the knowledge about the solid 357 
state of this important drug compound, contributes with new cases to the body of data of unexpected 358 
stoichiometric hybrid salt−cocrystals, and it is a new example of successful application of combined 359 
virtual/experimental methodologies for the discovery of new solid forms. 360 
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Legends to figures 503 
 504 
Figure. 1. Molecular structure of sildenafil. 505 
 506 
Figure. 2 SSIPs calculated for sildenafil. Blue spheres correspond to Hbond donors and red spheres to 507 
H-bond acceptors. 508 
 509 
Figure. 3 Fragments searched in multicomponent crystals in the CSD. 510 
 511 
Figure. 4 Crystal structure of tartaric acid salt of sildenafil. The most relevant interactions are 512 
highlighted. Channels filled by solvent molecules are highlighted with gray circles. 513 
 514 
Figure. 5 Sildenafil/tartrate cage in the crystal structure of tartaric acid salt of sildenafil. 515 
 516 
Figure. 6 Chains of carboxylate/carboxylic acid molecules linked by molecules of water in the hybrid 3-517 
hydroxybenzoic salt−cocrystal monohydrate. 518 
 519 
Figure. 7 Representation of the crystal structures of 3-hydroxybenzoic acid salt and hybrid 520 
salt−cocrystal of sildenafil. The most relevant interactions have been highlighted, and hydrogens have 521 
been partially omitted for clarity. Channels filled by THF and water molecules in the salt or 3-522 
hydroxybenzoic molecules in the hybrid salt−cocrystal are highlighted with gray circles. 523 
 524 
Figure. 8 Antiparallel dipole−dipole interactions established between stacked pyrimidinone rings in the 525 
crystal structures of 3-hydroxybenzoic acid salt (right) and hybrid salt-cocrystal (left). Differences in 526 
centroid−centroid distances measured between pyrimidinone rings and torsion angles of propyl groups 527 
are shown for each structure. 528 
  529 
Figure. 9 Chains of carboxylate molecules linked by molecules of water in the hybrid 3-hydroxybenzoic 530 
acid salt−cocrystal (left) and in the hybrid 3,4-dihydroxybenzoic acid salt−cocrystal (right). 531 
 532 
Figure. 10 Crystal structure of 3,4-dihydroxybenzoic acid hybrid salt−cocrystal. Self-assembled dimers 533 
formed through charge-assisted hydrogen bonds are highlighted. Hydrogens have been partially omitted 534 
for clarity. 535 
 536 
Figure. 11 Layers of alternate carboxylic (blue)/carboxylate (red) interactions. 537 
 538 
Figure. 12 Comparative solubility of SIL salts, cocrystals, and hybrid salt−cocrystals in 0. 1 N HCl (pH 539 
1.2). 540 
 541 
 542 
Figure. 13 Comparative solubility of SIL salts, cocrystals, and hybrid salt−cocrystals in phosphate 543 
buffer pH 6.5. 544 
 545 
 546 
Figure. 14 Comparative solubility of SIL salts, cocrystals, and hybrid salt−cocrystals in FaSSIF. 547 
 548 
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